Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse

Size: px
Start display at page:

Download "Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse"

Transcription

1 TRANSPLANTATION Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse Benny J. Chen, 1 Divino Deoliveira, 1 Xiuyu Cui, 1 Ngocdiep T. Le, 1 Jessica Son, 1 John F. Whitesides, 2 and Nelson J. Chao 1 1 Division of Cellular Therapy/Bone Marrow Transplantation, 2 Human Vaccine Institute, Department of Medicine and Immunology, Duke University Medical Center, Durham, NC Several groups, including our own, have independently demonstrated that effector memory T cells from non alloantigenprimed donors do not cause graft-versushost disease (GVHD). In the current study, we further investigated whether this approach could be extended to all memory T cells, and we studied the underlying mechanisms. Neither total memory T cells nor purified central memory T cells were able to induce GVHD. Memory T cells were at least 3-log less potent than bulk T cells in mediating GVHD. As expected, Introduction memory T cells failed to elicit cytotoxicity and proliferated poorly against alloantigens in standard 5-day mixed-lymphocyte cultures. However, the proliferative responses of memory T cells were more comparable with those of bulk and naive T cells when the culture time was shortened. Moreover, the frequencies of IL-2 secreting cells measured by 42-hour enzyme-linked immunosorbent spot (ELISPOT) assay were similar among naive, memory, and bulk T cells. These data indicated that memory T cells are able to respond to alloantigens initially but fail to develop to full potential. The abortive immune response, which was mediated by non alloantigen-specific memory T cells in response to alloantigens, may explain why memory T cells from unprimed and non alloantigen-primed donors could not induce GVHD. (Blood. 2007;109: ) 2007 by The American Society of Hematology Allogeneic stem cell transplantation offers the hope of cure for a wide variety of otherwise lethal malignant and nonmalignant diseases. 1 However, this procedure is associated with substantial risks, including graft-versus-host disease (GVHD), infection, and disease relapse. 1 These complications are intricately related to the function of mature T cells contained in the graft. 1,2 T cells mediate GVHD, 3 a life-threatening adverse effect that can occur after allogeneic stem cell transplantation. 1 Depletion of T cells from the graft is effective in preventing GVHD but is associated with increased risk for graft failure, leukemia relapse, and opportunistic infection. 2 Thus, the major challenge in allogeneic stem cell transplantation is how to transfer the T cell mediated beneficial effects without causing GVHD. Because the antigen specificity of each T lymphocyte is determined before its contact with antigen by random gene rearrangements in the thymus, 4 mature T cells can be divided into naive and memory subsets based on whether they have encountered their corresponding antigens. 5 Naive and memory T cells can be distinguished by cell surface markers. 5-7 We hypothesized that, if a donor has never encountered the host alloantigens, all host alloantigen specific T cells are exclusively contained in the naive T-cell compartment and that memory T cells from these animals would not cause GVHD. Based on this hypothesis, we have demonstrated that CD62L T cells (effector memory T cells [T EM ]) from unprimed or non host alloantigen primed donors do not induce GVHD. 8 Similar results have been reported by several other groups using different animal systems Based on the expression of homing molecules, such as CD62L, memory T cells can be further divided into central memory (T CM ; all CD62L memory T cells) and effector memory (T EM ; all CD62L T cells) subsets. 13,14 We asked whether the findings with T EM could be extended to all memory T cells. If our hypothesis is correct, all memory T cells, including T CM and T EM, should be unable to induce GVHD. To answer this question directly, we tested the ability of all memory T cells to induce GVHD. Moreover, we explored the mechanisms by which memory T cells failed to cause GVHD. Material and methods Mice BALB/c (H2 d ), C57BL/6 (H2 b ), and C3H/HeJ (H2 k ) were purchased from The Jackson Laboratories (Bar Harbor, ME). C57BL/Ka, CD45.1, Thy1.1 mice (gifts from Dr Jos Domen, Duke University, Durham, NC), which are congeneic to C57BL/6, were bred at Duke University. Female mice were primarily used in this study. Most of the unprimed donor mice were between 10 and 30 weeks of age. Some of the repeated experiments were performed using male or older donor mice (up to 20 months of age) or C57BL/Ka, CD45.1, Thy1.1 mice. No differences were observed when male, older, or C57BL/Ka, CD45.1, Thy1.1 donor mice were used (data not shown). Recipient mice were 7 to 12 weeks old when they underwent transplantation. The mice were housed in a specific pathogen-free facility throughout the study. T-cell depletion from bone marrow T cells were depleted from bone marrow using anti Thy1.2 antibody and complement according to a published protocol from our laboratory. 15 Submitted November 28, 2005; accepted November 22, Prepublished online as Blood First Edition Paper, December 5, 2006; DOI /blood The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked advertisement in accordance with 18 USC section by The American Society of Hematology BLOOD, 1 APRIL 2007 VOLUME 109, NUMBER

2 3116 CHEN et al BLOOD, 1 APRIL 2007 VOLUME 109, NUMBER 7 T-cell purification Splenic T cells were negatively selected by using T-cell enrichment columns (R&D Systems, Minneapolis, MN) followed by a negative selection procedure using anti major histocompatibility complex (MHC) class II (Ia), CD11b, and DX5 microbeads (Miltenyi Biotec, Auburn, CA). The purity of T cells was always greater than 95%. Sorting of memory T cells Purified T cells were first stained with biotinylated anti CD4 (RM4-5) and anti CD8 (53-6.7) Cy-Chrome conjugated anti CD44 (IM7), phycoerythrin (PE) conjugated anti CD45RB (16A), and fluorescein isothiocyanate (FITC) conjugated anti CD62L (MEL-14) antibodies followed by PE-Texas Red conjugated streptavidin (Caltag, South San Francisco, CA). Except where indicated, antibodies were purchased from BD PharMingen (San Jose, CA). Stained cells were sorted into naive (CD45RB CD62L CD44 /low ) and memory T-cell fractions (all other T cells except those with naive phenotype, including all the T cells with the following phenotypes: CD45RB CD62L CD44 high, CD45RB CD62L, and CD62L ) using FACS Vantage SE equipped with FACSDiva software (Becton Dickinson, San Jose, CA). 5,6 In some experiments, memory T cells (total) were sorted into T CM (all CD62L memory T cells, including T cells with the phenotypes CD45RB CD62L CD44 high and CD45RB CD62L ) and T EM (all CD62L T cells) through 4-way sorting. 13,14,16 To sort CD25 memory T cells, allophycocyanin (APC) conjugated anti CD25 (PC61) and PE-Cy5.5 conjugated anti CD44 (IM7; ebioscience, San Diego, CA) antibodies were used. To sort CD4 memory T cells, APC-conjugated anti CD4 (RM4-5; Caltag) antibody was used. The sorting strategy is shown in Figures 1A and 7A, and the post-sort analyses and the phenotypes of different T-cell subsets are shown in Figures 1B and 7B. Most of the unsorted control bulk T cells used in the study were not stained with antibodies. However, we tested the antibodies and found that they do not affect the ability of bulk T cells to induce GVHD or to proliferate against alloantigens (data not shown). Naive T cells, which were stained with antibodies and sorted together with memory T-cell subsets, were always included as a control. Responder cell doses were always adjusted based on T-cell content. Proliferation assay Proliferation assay has been described previously. 8 Graded numbers of purified T cells ( ) were plated in 96-well, flat-bottom culture plates with irradiated (20 Gy) allogeneic spleen cells or keyhole limpet hemocyanin (KLH; 100 g/ml, Pierce, Rockford, IL) plus irradiated (20 Gy) syngeneic spleen cells in a final volume of 200 L. After incubation at 37 C and 5% CO 2 for a certain period of time (96 hours, except where indicated), cultures were pulsed with 3 H-thymidine (1 Ci [0.037 MBq]/well). After another 16 hours of incubation, the cultures were harvested and counted in a MicroBeta Trilux liquid scintillation counter (EG&G Wallac, Turku, Finland). Triplicate cultures were set up for every cell population tested. Cytotoxic T-cell assay Cytotoxic T-cell assay has been described previously. 17 Graded numbers of responder cells were plated with irradiated (20 Gy) allogeneic spleen cells per well in 96-well, round-bottom plates. Plates were cultured at 37 C in a 5% CO 2 incubator for 112 hours. The cells were then tested in situ for lysis of 51 Cr-labeled 2-day concanavalin A (Con A) blast cells. After 4 hours of culture, supernatant was removed and counted in a MicroBeta Trilux liquid scintillation counter (EG&G Wallac) after it was mixed with SuperMix scintillator (EG&G Wallac). In each experiment, cultures were tested in parallel for lysis of irrelevant targets to ensure the specificity of the killing. Triplicate cultures were set up for every cell population tested. Spontaneous release was obtained by incubating target cells with stimulator cells only. Maximal release was obtained after treatment with 1% Igepal CA-630 (Sigma, St Louis, MO). The percentage of specific release was calculated as follows: ([Experimental release spontaneous release]/ [Maximal release spontaneous release]) 100 % specific release. Enzyme-linked immunosorbent spot assay Enzyme-linked immunosorbent spot (ELISPOT) assay was performed using ELISPOT kits (R&D Systems) according to the manufacturer s protocol. Graded numbers of C57BL/6 responder cells were incubated with /well irradiated (20 Gy) BALB/c spleen cells at 37 C and 5% CO 2 for 42 hours in the microplates. Wells were washed 3 times before the detection anti cytokine antibody was added. Microplates were then incubated at 4 C overnight. At the end of incubation, the plates were washed 3 times again, then 100 L streptavidin-ap was added to each well. After 2 hours of incubation at room temperature, the microplates were washed 3 times, and the substrate solution (BCIP/NBT chromogen) was added. Plates were further incubated in the dark at room temperature for 1 hour. The chromogen solution was then discarded from the microplates, and the microplates were rinsed with distilled water. After the microplates were dry, the ELISPOTS, which represented the number of cytokine-secreting cells, were scored using a KS ELISPOT reader (Carl Zeiss Vision, Hallbergmoos, Germany). Triplicate cultures were set up for every cell population tested. GVHD model Lethally irradiated (BALB/c, 8.5 Gy; C3H/HeJ, 9.5 Gy; C57BL/6, 10.5 Gy) mice were injected intravenously through the tail vein with T-cell depleted bone marrow (TCD BM) cells and purified T cells ( were used for most of the experiments, except where indicated). Recipients were weighed once every 7 days. Survival and clinical evidence of GVHD, such as skin changes (hair loss and erythema), diarrhea, and hunched posture, were monitored daily. Moribund mice were humanely killed according to an animal protocol approved by the Duke University Institutional Animal Care and Use Committee. Except where indicated, the experiments were performed in the C57BL/63BALB/c system. Histopathological analysis of GVHD Biopsy samples were taken from skin, tongue, lung, intestine, liver, and spleen and were stored in buffered formalin. Specimens were then embedded in paraffin, cut into 5- m sections, and stained with hematoxylineosin. Slides were examined under a light microscope (Zeiss Standard 25; Carl Zeiss, Thornwood, NY) by B.J.C. in a blinded manner and further verified independently by N.T.L. (blinded to experimental groups). To detect subclinical acute and chronic GVHD, we scored histological GVHD using a semiquantitative scoring system adapted from systems previously published by other groups, with additional measurements of histological changes of chronic GVHD. Slides were scored on the basis of inflammation, tissue damage, and fibrosis. The scoring system for each category measured the extent and the severity of the histological changes: 0, normal; 0.5, focal and rare; 1, focal and mild; 2, diffuse and mild; 3, diffuse and moderate; 4, diffuse and severe. Scores were subsequently added to provide a total score for each specimen. Minimum score was 0, and maximum score was 12 for each target organ. A score greater than 0.5 in any category or a total score more than 1.5 was considered positive for GVHD. Specific changes examined included inflammatory infiltrates, apoptosis of keratinocytes, separation of dermo-epidermal junction, and formation of cleft, follicular dropout, and fibrosis in the skin; inflammation, apoptosis of bile duct epithelial cells, apoptosis of hepatocytes, cholestasis, fibrosis, and parenchyma in the liver; and lamina propria inflammatory cell infiltrate, crypt regeneration, crypt epithelial cell apoptosis, crypt loss, mucosal ulceration, and fibrosis in the intestine. 18,19,22 Only skin, liver, and intestine slides were scored. Slides from other tissues (tongue, lung, and spleen) were examined but not scored because the criteria for GVHD in these tissues have not yet been established. The histologic pictures were taken under an Olympus Vanox-S light microscope (Olympus, Center Valley, PA) using an Olympus DP11C camera. We used a 40 /0.7 NA objective lens. The total magnification of the picture was 100 (objective, 40; photolens, 2.5). The original, unmodified pictures were used in this paper.

3 BLOOD, 1 APRIL 2007 VOLUME 109, NUMBER 7 MEMORY T CELLS DO NOT CAUSE GVHD 3117 Immunization Each donor mouse was injected intraperitoneally with 50 g KLH emulsified in complete Freund adjuvant (Pierce). Donor animals were used more than 4 weeks after immunization. Coculture assay The assay was performed as previously described. 23 Briefly, T cells with putative regulatory activity were added to the mixed lymphocyte cultures. Cocultured cells were added at different ratios to the responder cells. Bulk T cells and irradiated (20 Gy) responder spleen cells were included as controls. Experiments were performed in 96-well, flat-bottom culture plates with a total volume of 200 L/well. Proliferation was measured as described after 112-hour culture. Statistical analysis Data are represented as mean SD or as mean SD. Comparison between groups was performed by analysis of variance (ANOVA) because all the experiments involved more than 2 groups in this study. When a difference was detected by ANOVA among the groups, the Fisher protected least significant difference test was used to determine the difference between 2 groups. Survival data were analyzed by log rank test. All statistical analyses were performed using StatView software (SAS Institution, Cary, NC). P values below.05 were considered significant. Results Memory T cells from unprimed mice respond poorly to alloantigens in 5-day mixed-lymphocyte cultures Others and we have demonstrated that T EM cannot cause GVHD In this study, we further explored whether these observations could be extended to all memory T cells. To test this, we sorted T cells into naive and memory (defined as all T cells except naive T cells, including T EM and T CM ) populations (Figure 1A-B) and first evaluated their ability to respond to alloantigens using optimal 5-day proliferation and CTL assays. As demonstrated in 2 different systems (Figure 1C), memory T cells proliferated poorly against alloantigens compared with naive and bulk T-cell controls. Similar results were observed in 2 other animal systems (C57BL/6-anti- C3H/HeJ, BALB/c-anti-C3H/HeJ; data not shown). Consistent with the results in the proliferation assays, memory T cells were unable to elicit cytotoxicity in response to alloantigens, whereas the cytotoxicity elicited by naive and bulk T cells was readily Figure 1. Proliferation and cytotoxicity. Sorted T-cell subsets were cultured with irradiated allogeneic spleen cells for 5 days before they were tested for proliferation and cytotoxicity. Results represent mean SD of triplicate wells. (A) Sorting strategy. Enriched T cells were stained with anti-cd4, anti-cd8, anti-cd44, anti-cd45rb, and anti-cd62l antibodies. We first gated on CD4/CD8 T cells. CD45RB CD62L T cells (region A) were further separated into 2 populations based on the expression of CD44 (A1, CD45RB CD62L CD44 /low ; A2, CD45RB CD62L CD44 high ). Cells were sorted into naive (A1) and memory (all other T cells except naive [B C A2]) phenotype T cells. In some experiments (Figure 5), memory (total) T cells were further separated into T EM (region B) and T CM (C A2) based on the expression of CD62L. Shown in the third column are cells from regionain the second column. Numbers represent percentages of parent gates. Donor mice for this sort were 4 to 6 months old. (B) Phenotypes of sorted T-cell subsets. Shown in the second column are cells from region A in the first column. Data presented in the last 2 columns were not from post-sort analyses. Logarithmic displays were used in all histograms or dot plots except those in the last column in which logicle displays (biexponential displays) were used. These data represent the results of at least 4 similar experiments. (C) Mixed lymphocyte reaction. Proliferation was determined by 3 H-thymidine incorporation. The responder alone was always lower than 200 cpm. Data represent the results of 3 to 4 similar experiments. (D) Cytotoxic T-lymphocyte assay. Cytotoxicity was measured by 4-hour 51 Cr release assay. *P.01, memory versus other groups; #P.01, naive versus bulk.

4 3118 CHEN et al BLOOD, 1 APRIL 2007 VOLUME 109, NUMBER 7 detectable (Figure 1D). It is important to point out that, unlike FVB/N mice, as previously reported, 24 young (8-12 weeks old) and old (9-10 months old) C57BL/6 mice responded similarly against BALB/c and C3H/HeJ antigens in proliferation assays (data not shown). Memory T cells from unprimed donors were unable to induce GVHD We then tested whether memory T cells could induce GVHD in several different systems (C57BL/63BALB/c, C57BL/63C3H/ HeJ, BALB/c3C57BL/6). T cells ( /mouse) were transplanted into lethally irradiated recipients together with T-cell depleted bone marrow (TCD BM) cells. GVHD did not develop in any of the recipients of memory T cells. In contrast, lethal GVHD developed in almost all recipients of naive and bulk T cells. As a result, almost all memory T-cell recipients survived more than 100 days after transplantation, whereas all naive and almost all bulk T-cell recipients died of GVHD within 80 days of transplantation (Figure 2A). Body weights in some of the memory T-cell recipients were lower (though not statistically significant) than in the recipients of T-cell depleted bone marrow, but body weights on day 98 were not different from those on day 0 (Figure 2A). Moreover, no histological evidence was found in recipients of memory T cells (Figure 2B; Table 1). These data demonstrate that memory T cells from unprimed mice are unable to induce GVHD in major histocompatibility complex (MHC) mismatched recipients. To quantify the degree of GVHD reduction after depletion of naive T cells, we titrated the cell dose down in the control bulk T-cell group but did not increase the memory T-cell dose because it was technically difficult to sort greater numbers of cells than cells/mouse for transplantation. As demonstrated in Figure 2C, purified bulk T cells induced GVHD in a dose-dependent manner. As expected, lethal GVHD developed in all recipients of T cells, and they died within 1 month of transplantation. GVHD developed in 4 of 5 mice in the T cell group, and 1 died on day 98. GVHD developed in 3 of 5 of the recipients of T cells, and 2 of them died within 200 days of transplantation. GVHD developed in 2 of 5 recipients of T cells, and 1 of them died on day 162. Clinical data were further confirmed by histological examination (data not shown). These data suggest that Figure 2. Memory T cells do not cause GVHD. Sorted T-cell subsets were transplanted into lethally irradiated recipients along with T-cell depleted BM cells. Mice were monitored for the development of GVHD. (A) Survival and weight curves. Body weight data are presented as mean SD. For survival, P.05 (memory versus bulk or naive). For body weight, P was not significant (memory versus TCD BM only in all time points after day 7). No signs of GVHD were observed in the single memory T-cell recipient (C57BL/63C3H/HeJ) that died during observation. Data were pooled from several independent similar experiments (3 for C57BL/63BALB/c, 1 for BALB/ c3c57bl/6, 2 for C57BL/63C3H/HeJ). (B) Histological analysis (hematoxylin and eosin stain, 100). Biopsy specimens were obtained from BALB/c recipients of C57BL/6 T cells on day 32 for bulk and naive T-cell groups and day 120 for TCD BM only and memory T-cell groups. (C) Dose-dependent T-cell response in GVHD. Graded numbers of purified C57BL/6 T cells were transplanted into lethally irradiated BALB/c recipients along with T-cell depleted BM. Mice were monitored for the development of GVHD. For survival, P.05 ( versus other groups). For body weight, P.05 (TCD BM only versus ,1 10 5, and at all time points later than day 14 except on day 70). *P.05 ( versus TCD BM only on days 77, 84, and 98). TCD BM indicates T-cell depleted BM.

5 BLOOD, 1 APRIL 2007 VOLUME 109, NUMBER 7 MEMORY T CELLS DO NOT CAUSE GVHD 3119 Table 1. Recipients of memory T cells do not have histological GVHD Group GVHD scores Skin Liver Colon TCD BM only, n 4 Mouse Mouse Mouse Mouse Bulk, n 3 Mouse Mouse Mouse Naive, n 3 Mouse Mouse Mouse Memory, n 4 Mouse Mouse Mouse Mouse Tissues were harvested from representative mice shown in Figure 2A (C57BL/ 63BALB/c). Similar results were observed in 2 other systems (BALB/c3C57BL/6 and C57BL/63C3H/HeJ). Tissues from recipients of bulk and naive T cells were harvested between days 23 and 36. Tissues from TCD BM only and memory T-cell recipients were harvested after recipients were electively killed on day 120. Shown are individual scores of maximum scores of 12 for each target organ. TCD BM indicates T-cell-depleted BM. memory T cells are at least 3-log less potent at inducing GVHD than bulk T cells because GVHD did not develop in any of the memory T-cell recipients receiving T cells (Figure 2A-B; Table 1). Memory T cells from KLH-primed donors are unable to induce GVHD To be certain that the true functional memory T cells are unable to induce GVHD, we repeated the experiments using T cells from KLH-primed donors. Although memory T cells from KLH-primed mice proliferated vigorously against KLH (Figure 3A), proliferation against alloantigens remained low (Figure 3B). In contrast, naive T cells responded vigorously to alloantigens (Figure 3B) but not to KLH (Figure 3A). These data demonstrate that the memory phenotype T cells used in the experiments were true functional memory T cells. We next tested their ability to induce GVHD in vivo. Similar to those from unprimed donors (Figure 2A-B), memory T cells from KLH-primed donors were unable to induce GVHD (Figure 3C-D). In contrast, naive and bulk T cells from KLH-primed donors induced lethal GVHD (Figure 3C-D). Histological analyses were consistent with the clinical observations (data not shown), indicating that functional memory T cells from non alloantigen-primed animals were unable to induce GVHD. Early alloresponses mediated by memory T cells from unprimed mice Our next question was why memory T cells lack the ability to induce GVHD. Although proliferative responses in the memory T-cell group were very low (Figure 1C), we observed some counts in the standard optimal 5-day MLR assays (eg, cpm for /well in the C57BL/6 anti-balb/c model). Moreover, microscopy revealed that memory T cells did expand initially on challenge with alloantigens. However, when observed on day 5 after the initiation of culture, the colonies were smaller and most of the cells appeared to be dying. These observations prompted us to study the kinetics of the proliferative response mediated by memory T cells. We performed MLR assays again and harvested the cells at various time points after the initiation of culture. In C57BL/6 anti-balb/c mice, the proliferative responses mediated by memory T cells were close to those mediated by naive and bulk T cells when cultured for 2 and 3 days (Figure 4A). In BALB/c-anti C57BL/6 mice, the proliferative responses mediated by memory T cells were even higher than those mediated by naive T cells when cultured for 2, 3, and 4 days (Figure 4A). Similar to the data presented in Figure 1C, the proliferative responses mediated by memory T cells were significantly lower than those mediated by naive and bulk T cells when measured after 5 days of culture (Figure 4A), the peak proliferation time for bulk T cells (data not shown). Because memory T cells have similar ability to proliferate in the first several days, we considered whether memory T cells were able to secrete IL-2 in response to alloantigens because IL-2 production is an important event in T-cell activation and expansion. 25 As illustrated in Figure 4B, the frequencies of alloantigen-specific IL-2 production cells in memory T cells were similar to those in naive T cells (128 vs 147 for BALB/c stimulators, 109 vs 150 for C3H/HeJ stimulators) and were not different from those in bulk T cells. Taken together, these data strongly suggest that memory T cells are able to respond initially but fail to reach their full potential on challenge with alloantigens. Purified central memory T cells are unable to induce GVHD The inability of T EM to induce GVHD was thought to result from their inability to home to secondary lymphoid organs, such as lymph nodes and Peyer patches. 24,26 Moreover, it was demonstrated that CD8 T EM had a decreased ability to mediate protective Figure 3. Memory T cells from KLH-primed donors do not cause GVHD. Donor C57BL/6 mice were first immunized with KLH antigens. More than 4 weeks later, T cells were obtained from these mice and were sorted into different T-cell subsets. Responses against KLH antigens and alloantigens were evaluated by in vitro proliferation assays and in vivo GVHD assay (C57BL/63BALB/c). Proliferation was detected by 3 H-thymidine incorporation after 5 days in culture. Proliferation assays have been repeated twice with similar results. GVHD data were from a single experiment. (A) Proliferation against KLH antigens. Results represent mean SD of triplicate wells. (B) Proliferation against alloantigens. Results represent mean SD of triplicate wells. (C) Survival in GVHD assay. P.05 (memory versus bulk or naive). (D) Weight curve in GVHD assay. Data are represented as mean SD. P.05 (memory versus other groups after day 21). TCD BM indicates T-cell depleted BM. KLH indicates keyhole limpet hemocyanin. *P.05, memory versus other groups; #P.05, naive versus bulk.

6 3120 CHEN et al BLOOD, 1 APRIL 2007 VOLUME 109, NUMBER 7 Figure 6. CD4 memory T cells do not cause GVHD. Sorted CD4 T-cell subsets were transplanted into lethally irradiated recipients along with T-cell depleted BM cells. Mice were monitored for the development of GVHD. (A) Survival. P.05, CD4 memory versus bulk or CD4 naive; P.05, bulk versus CD4 naive. (B) Weight curve. P.05, CD4 memory versus TCD BM only after day 42. Figure 4. Early alloresponses mediated by memory T cells from unprimed mice. Sorted T-cell subsets were cultured with irradiated allogeneic stimulators. All experiments were repeated at least twice and yielded similar results. Results represent mean SD of triplicate wells. (A) Kinetics of proliferative response. Cells were harvested at different times after the initiation of culture. Proliferation was determined by 3 H-thymidine incorporation. Proliferation rates in the syngeneic controls were less than 10%, 5%, and 1% of the experimental groups for 2-, 3-, and 4-day cultures, respectively. (B) IL-2 production. Frequencies of IL-2 producing cells were determined by ELISPOT assay. IL-2 indicates interleukin-2; ELISpot, enzymelinked immunosorbent spot assay. *P.05, memory versus other groups; #P.05, memory versus naive. immunity against viruses compared with CD8 T CM. 14 Thus, it was of interest to test whether T CM cells, which have the capacity to home to secondary lymphoid organs 26 and are more efficient in eliciting protective immunity, 14 could induce GVHD. Data presented in Figure 2A-B demonstrate that total memory T cells, which contain approximately 20% ( )T CM and 80% ( )T EM (Figure 1A-B), do not cause GVHD. These data strongly suggest that T CM cells also lack the ability to induce Figure 5. Purified central memory T cells do not cause GVHD. Sorted T-cell subsets were transplanted into lethally irradiated recipients, along with T-cell depleted BM cells. Mice were monitored for the development of GVHD. Data were pooled from 3 independent experiments. (A) Survival. P.05, T CM or T EM versus naive. (B) Weight curve. P not significant, TCD BM only versus T EM or T CM. GVHD because as few as bulk T cells are able to induce GVHD in this model (Figure 2C). To determine the role of T CM in GVHD more definitively, we isolated T CM cells by cell sorting (Figure 1A-B) and tested their ability to induce GVHD in vivo. C57BL/6 splenic T CM cells ( /mouse) were transplanted into lethally irradiated BALB/c recipients along with T-cell depleted bone marrow. Similar to T-cell depleted bone marrow alone and T EM recipients, T CM recipients did not develop GVHD, and all the mice in this group survived more than 100 days after transplantation (Figure 5A-B). In contrast, all naive T-cell recipients developed lethal GVHD and died within 40 days of transplantation (Figure 5A-B). These clinical observations were further confirmed by histological analyses (data not shown). Our data definitively demonstrated that T CM cells are unable to induce GVHD, as has been found with T EM cells 8. CD4 memory T cells are unable to induce GVHD Although proliferation mediated by memory T cells was low, it was detectable in 5-day culture (Figure 1C). However, CTL activity was completely undetectable (Figure 1D). These observations might suggest that the lack of capability of memory T cells to induce GVHD was the result of defective CTLs. To exclude this possibility, we tested the effect of purified CD4 memory T cells on GVHD. CD8 CTL cells were not involved. We isolated CD4 memory T cells by cell sorting and tested them in the C57BL/ 63BALB/c model. Sorted CD4 memory T cells ( /mouse) were transplanted into lethally irradiated recipients together with T-cell depleted bone marrow. As demonstrated in Figure 6, lethal GVHD developed in all recipients of CD4 naive and bulk T cells, and they died shortly after transplantation (naive, less than 10 days; bulk, less than 60 days). In contrast, lethal GVHD did not develop in any of the recipients of memory T cells; all survived more than 100 days after transplantation. Body weights in CD4 recipients of memory T cells were significantly lower than in recipients of TCD BM only, suggesting that the former might have mild GVHD. However, these mice did not have any other signs of GVHD. Moreover, the body weights of CD4 memory T cell recipients were the same as baseline (Figure 6B, day 0). The difference in the body weights was in fact a result of increased body weights in the TCD BM group (Figure 6B). In addition, we performed detailed histological analyses on these mice and did not find any histological evidence of GVHD (Table 2), indicating that CD4 memory T cells alone were unable to induce GVHD and suggesting that the lack of ability of memory T cells to induce GVHD was not a result of defective CTLs.

7 BLOOD, 1 APRIL 2007 VOLUME 109, NUMBER 7 MEMORY T CELLS DO NOT CAUSE GVHD 3121 Table 2. Recipients of CD4 memory T cells do not have histological GVHD Group GVHD scores Skin Liver Colon TCD BM only, n 5 Mouse Mouse Mouse Mouse Mouse CD4 naive, n 5 Mouse Mouse Mouse ND Mouse ND Mouse CD4 memory, n 5 Mouse Mouse Mouse Mouse Mouse 5 ND 0 0 Tissues were harvested from representative mice shown in Figure 6. Tissues from recipients of CD4 naive T cells were harvested between day 8 and day 9. Tissues from recipients of TCD BM only and memory T cells were harvested after recipients were electively killed on day 182. Shown are individual scores of maximum scores of 12 for each target organ. TCD BM indicates T-cell-depleted BM; ND, not determined. Regulatory T cells are not responsible for the low alloresponse mediated by memory T cells Memory T cells from KLH-primed animals were able to proliferate against KLH (Figure 3A), making it unlikely that regulatory T cells, especially CD62L-expressing CD4 CD25 cells, 27,28 were responsible for the low alloresponse mediated by the memory T-cell population (Figures 1-6). To exclude this possibility, we performed several experiments. First, we examined whether CD4 CD25 cells were enriched in memory T-cell subsets. As illustrated in Figure 1A-B, the percentages of CD4 CD25 cells among total T cells (5% vs 5%-10%) and among CD4 T cells (6% vs 6%-18%; data not shown) were only slightly increased in all memory T-cell subsets. Second, we depleted CD25 cells from the memory T-cell fraction (Figure 7A-B) and tested their ability to respond to alloantigens through in vitro proliferation and in vivo GVHD assays. As demonstrated in Figure 7C, CD25 T EM and T CM responded poorly to alloantigens. CD25 T CM cells were defective in causing GVHD (Figure 7D), as were T CM cells (Figure 5). We did not study CD25 T EM (CD62L ) in the in vivo assays because it is known that CD62L regulatory T cells have limited ability to inhibit GVHD 27,28 and that CD4 CD25 regulatory T cells do not account for the inability of CD4 T EM cells to induce GVHD. 10 Data from these experiments indicated that CD4 CD25 regulatory T cells were not responsible for the memory T-cell mediated low alloresponse. Finally, we performed a coculture experiment to exclude the involvement not only of CD4 CD25 but also of other putative subsets of regulatory T cells. We added sorted memory T cells from C57BL/6 mice to a mixed lymphocyte culture consisting of C57BL/6 T cells and irradiated BALB/c spleen cell stimulators. As demonstrated in Figure 7E, memory T cells could not inhibit the alloresponses, indicating that regulatory T cell do not play a major role in low alloresponse mediated by memory T cells. Discussion Several groups, including our own, have independently demonstrated that T EM cells are unable to induce GVHD in different animal models The first goal of the current study was to determine whether the observations on T EM could be extended to all memory T cells. Our in vivo data clearly demonstrated that the GVHD-inducing potential was exclusively contained in naive phenotype T cells and that memory phenotype T cells did not cause GVHD in unprimed (Figure 2A-B; Table 1) and non alloantigen-primed mice (Figure 3). Moreover, sorted T CM (Figure 5) and CD4 memory T (Figure 6; Table 2) cells were unable to induce GVHD. Because it is technically difficult to sort more cells than cells/mouse for transplantation, we titrated the cell dose down in the control bulk T-cell group rather than increase the cell dose of memory T cells to quantify the degree of GVHD reduction. Titration data (Figure 2C) demonstrated that the ability of memory T cells to induce GVHD is at least 3-log decreased because as few as bulk T cells were able to induce GVHD whereas as many as memory T cells were unable to cause GVHD (Figure 2A-B; Table 1). Such dramatic decrease in the ability to induce GVHD may allow the transfer of higher number of T cells than is currently possible, leading to stronger immune effects. Thus, this strategy may have a positive impact on the safety and broader application of allogeneic stem cell transplantation. Another major goal of the current study was to understand why memory T cells are unable to induce GVHD. Our working hypothesis was that memory T cells from unprimed and non alloantigen-primed animals do not contain alloantigen-specific T cells and, therefore, are unable to induce GVHD. However, even if our hypothesis is correct, the question remains: why is it that non alloantigen-specific memory T cells, which likely contain T cells cross-reactive with MHC antigens, 29 do not induce GVHD in MHC-mismatched recipients? Low responses mediated by memory T cells in 5-day MLR and CTL assays (Figure 1) seem to corroborate our hypothesis. However, when cultured for shorter periods of time, the responses mediated by memory T cells in response to alloantigens were not different from those mediated by naive and bulk T cells (Figure 4). These data indicated that memory T cells are able to respond to alloantigens initially but are unable to maintain the proliferative response. These data further suggest that unprimed memory T cells do contain alloreactive T cells defined by in vitro proliferation. However, these cells do not appear to be alloantigen specific because the responses mediated by these cells are different from those mediated by true alloantigen-specific memory T cells 30 (Figure 4). Even though we do not fully understand the mechanism(s), we speculate that these are non allospecific memory T cells cross-reacting with alloantigens at a level that does not lead to full activation. If they are reflecting non allospecific memory T cells cross-reacting with alloantigens, these observations may explain why the proliferative alloresponses mediated by unprimed memory T cells are so different between different models 24,31 (Figure 4A) because different cross-reactive T cells are likely involved in different systems. Thus, the inability of memory T cells from unprimed donors to maintain the responses on challenge with alloantigens (Figure 4) may explain why they are unable to induce GVHD. It was proposed that the lack of capability of T EM cells to induce GVHD is the result of their inability to home to lymph nodes and Peyer patches. 24 Our data using purified T CM cells

8 3122 CHEN et al BLOOD, 1 APRIL 2007 VOLUME 109, NUMBER 7 Figure 7. Regulatory T cells are not responsible for low alloresponse mediated by memory phenotype T cells. (A) Sorting strategy for CD25 memory T cells. We first gated on CD25 T cells. The rest of the sorting strategies for naive and memory phenotype T cells are the same as those described in Figure 1A. Shown in the third column are cells from region A in the second column. Numbers represent percentages of parent gates. (B) Phenotypes of sorted T-cell subsets. Shown in the third column are cells from region A in the second column. (C) Mixed lymphocyte reaction (C57BL/6 anti-balb/c). Proliferation was determined by 3 H-thymidine incorporation. Results represent mean SD of triplicate wells. Data are representative of 2 experiments with similar results. *P.01, memory versus other groups; #P.01, naive versus bulk. (D) In vivo GVHD (C57BL/63BALB/c) assay. Sorted T-cell subsets were transplanted into lethally irradiated recipients along with T-cell depleted BM cells. Mice were monitored for the development of GVHD. Data were pooled from 2 independent experiments. For survival, P.05 (T CM versus naive). For body weight, P was not significant for TCD BM only versus T CM. (E) Coculture assay. T cells with putative regulatory activity from C57BL/6 mice were added to the 5-day mixed lymphocyte cultures (C57BL/6 anti-balb/c). Cocultured cells were added to the responder cells at 2 different ratios. Proliferation was determined by 3 H-thymidine incorporation. Results represent mean SD of triplicate wells. Data are representative of 3 experiments with similar results. *P.05, bulk versus medium. (Figure 5), which are able to home to lymph nodes and Peyer patches, 26 suggest that other mechanisms are involved. In fact, defects in homing cannot explain why the in vitro responses were dramatically decreased (Figures 1C-D, 7C). It was noted that T CM cells contain fewer CD4 T cells than other T-cell subsets (Figure 1B), which may contribute to the lack of GVHD in T CM recipients (Figure 5) because CD8 T cells have less ability to induce GVHD than do CD4 T cells in this model. 32,33 However, the decreased percentage of CD4 T cells cannot completely explain why T CM recipients are free of GVHD (Figure 5) because T CM recipients do contain sufficient numbers of CD4 T cells, which have been demonstrated to be able to induce lethal GVHD in this model 33 (Figure 2C). CTLs play a critical role in tissue damage in GVHD. 34 Decreased CTL activity in memory T cells (Figure 1D) may result in reduced GVHD. However, our data, presented in Figure 6 and Table 2, strongly suggest that defective CTLs did not play a pivotal role because purified CD4 memory T cells, which do not contain CD8 CTLs, were also unable to induce GVHD. Lack of GVHD could be attributed to increased regulatory T-cell activity in the graft. 35 However, memory T cells depleted of CD4 CD25 regulatory T cells remained low responsive against alloantigens (Figure 7C-D). Moreover, the coculture assay failed to detect any regulatory activity in memory T cells (Figure 7E). These data indicate that regulatory T cells are not responsible for the inability of memory phenotype T cells to induce GVHD. In conclusion, we have demonstrated that all memory T cells, including T EM and T CM, are unable to induce GVHD and that GVHD-inducing T cells exclusively express the naive phenotype in unprimed donors. The lack of capability of memory T cells from unprimed donors to induce GVHD may be a result of abortive alloresponses mediated by non alloantigen-specific memory T cells. Regulatory T cells do not play a major role in this process. This novel approach may allow the transfer of recall T-cell immunity without causing GVHD. The better understanding of memory T-cell responses in GVHD will facilitate the clinical translation of this approach to improve the safety, broaden the scope, and enhance the effectiveness of allogeneic stem cell transplantation. Acknowledgments This work was supported by National Institutes of Health grants P01-HL67314 and P01-CA We thank Patti McDermott and Danielle King from the Duke Human Vaccine Institute Flow Cytometry Core Facility (supported

9 BLOOD, 1 APRIL 2007 VOLUME 109, NUMBER 7 MEMORY T CELLS DO NOT CAUSE GVHD 3123 by National Institute of Health grant AI ) for cell sorting and Dr Gwynn Long for critical reading of the manuscript. Authorship Contribution: B.J.C. designed the research, performed the research, analyzed the data, and wrote the paper. D.D. performed the research. X.C. designed the research, performed the research, and analyzed the data. N.T.L. performed the research and analyzed the data. J.S. designed the research, performed the research, and analyzed the data. J.W.F. designed the research, performed the research, and analyzed the data. N.J.C. provided advice on experimental design and manuscript preparation. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Benny J. Chen, Division of Cellular Therapy/ BMT, Department of Medicine, Duke University Medical Center, Box 3289, 247A Carl Bldg, Durham, NC 27710; chen0032@mc.duke.edu. References 1. Thomas ED, Blume KG, Forman SJ. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science; Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98: Korngold B, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice: prevention by removing mature T cells from marrow. J Exp Med. 1978;148: Ada GL, Nossal G. The clonal-selection theory. Sci Am. 1987;257: Sprent J. T-memory and B-memory cells. Cell. 1994;76: Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol. 1998;16: Bradley LM, Atkins GG, Swain SL. Long-term CD4 memory T-cells from the spleen lack Mel- 14, the lymph-node homing receptor. J Immunol. 1992;148: Chen BJ, Cui XY, Sempowski GD, Liu CX, Chao NJ. Transfer of allogeneic CD62L( ) memory T cells without graft-versus-host disease. Blood. 2004;103: Spickett GP, Brandon MR, Mason DW, Williams AF, Woollett GR. MRC OX-22, a monoclonal antibody that labels a new subset of T lymphocytes and reacts with the high molecular weight form of the leukocyte-common antigen. J Exp Med. 1983; 158: Anderson BE, McNiff J, Yan J, et al. Memory CD4 T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112: Zhang Y, Joe G, Zhu J, et al. Dendritic cell-activated CD44 hi CD8 T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood. 2004;103: Xystrakis E, Bernard I, Dejean AS, et al. Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RC high but not the CD45RC low subset. Eur J Immunol. 2004;34: Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401: Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003; 4: Chen BJ, Cui XY, Sempowski GD, Domen J, Chao NJ. Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood. 2004;103: Hengel RL, Thaker V, Pavlick MV, et al. L-selectin (CD62L) expression distinguishes small resting memory CD4( ) T cells that preferentially respond to recall antigen. J Immunol. 2003;170: Chen BJ, Cui X, Chao NJ. Addition of a second, different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation. Blood. 2002;99: Anderson BE, McNiff JM, Jain D, et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 2005;105: Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90: Snover DC, Weisdorf SA, Ramsay NK, McGlave P, Kersey JH. Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology. 1984;4: Snover DC, Weisdorf SA, Vercellotti GM, et al. A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol. 1985; 16: Heymer B. Clinical and Diagnostic Pathology of Graft-Versus-Host Disease. Heidelberg, Germany: Springer; Chen BJ, Chen Y, Cui X, Fidler JM, Chao NJ. Mechanisms of tolerance induced by PG in a bone marrow transplantation model. Transplantation. 2002;73: Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106: Kuby J. Immunology. New York, NY: WH Freeman; Gallatin WM, Weissman IL, Butcher EC. A cellsurface molecule involved in organ-specific homing of lymphocytes. Nature. 1983;304: Taylor PA, Panoskaltsis-Mortari A, Swedin JM et al. L-selectin(hi) but not the L-selectin(lo) CD4 25 T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood. 2004; 104: Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L subpopulation of CD4 CD25 regulatory T cells protects from lethal acute GVHD. Blood. 2005;105: Ashwell JD, Chen C, Schwartz RH. High-frequency and nonrandom distribution of alloreactivity in T-cell clones selected for recognition of foreign antigen in association with self class II molecules. J Immunol. 1986;136: Matesic D, Lehmann PV, Heeger PS. High-resolution characterization of cytokine-producing alloreactivity in naive and allograft-primed mice. Transplantation. 1998;65: Gamadia LE, Remmerswaal EB, Surachno S, et al. Cross-reactivity of cytomegalovirus-specific CD8( ) T cells to allo-major histocompatibility complex class I molecules. Transplantation. 2004;77: Palathumpat V, Dejbakhsh-Jones S, Strober S. The role of purified CD8 T cells in graft-versusleukemia activity and engraftment after allogeneic bone marrow transplantation. Transplantation. 1995;60: Zeng D, Hoffmann P, Lan F, et al. Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. Blood. 2002;99: Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996;183: Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4( )CD25( ) regulatory T cells suppress lethal acute graft-versushost disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:

10 : doi: /blood originally published online December 5, 2006 Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse Benny J. Chen, Divino Deoliveira, Xiuyu Cui, Ngocdiep T. Le, Jessica Son, John F. Whitesides and Nelson J. Chao Updated information and services can be found at: Articles on similar topics can be found in the following Blood collections Immunobiology and Immunotherapy (5574 articles) Transplantation (2285 articles) Information about reproducing this article in parts or in its entirety may be found online at: Information about ordering reprints may be found online at: Information about subscriptions and ASH membership may be found online at: Blood (print ISSN , online ISSN ), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC Copyright 2011 by The American Society of Hematology; all rights reserved.

MATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All

MATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All MATERIALS AND METHODS Antibodies (Abs), flow cytometry analysis and cell lines Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All other antibodies used

More information

Canberra, Australia). CD11c-DTR-OVA-GFP (B6.CD11c-OVA), B6.luc + and. Cancer Research Center, Germany). B6 or BALB/c.FoxP3-DTR-GFP mice were

Canberra, Australia). CD11c-DTR-OVA-GFP (B6.CD11c-OVA), B6.luc + and. Cancer Research Center, Germany). B6 or BALB/c.FoxP3-DTR-GFP mice were Supplemental Materials and Methods Mice Female C57BL/6 (B6, I-E null, H-2 b ), BALB/c (H-2 d ) + ), FVB/N (H-2 q, I-E null, CD45.1 + ), and B6D2F1 (H-2 b/d ) mice were purchased from the Animal Resources

More information

Supplementary Figure Legends. group) and analyzed for Siglec-G expression utilizing a monoclonal antibody to Siglec-G (clone SH2.1).

Supplementary Figure Legends. group) and analyzed for Siglec-G expression utilizing a monoclonal antibody to Siglec-G (clone SH2.1). Supplementary Figure Legends Supplemental Figure : Naïve T cells express Siglec-G. Splenocytes were isolated from WT B or Siglec-G -/- animals that have not been transplanted (n= per group) and analyzed

More information

ASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS

ASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);

More information

Introduction TRANSPLANTATION. Defu Zeng, Petra Hoffmann, Fengshuo Lan, Philip Huie, John Higgins, and Samuel Strober

Introduction TRANSPLANTATION. Defu Zeng, Petra Hoffmann, Fengshuo Lan, Philip Huie, John Higgins, and Samuel Strober TRANSPLANTATION Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation

More information

Supplementary Information:

Supplementary Information: Supplementary Information: Follicular regulatory T cells with Bcl6 expression suppress germinal center reactions by Yeonseok Chung, Shinya Tanaka, Fuliang Chu, Roza Nurieva, Gustavo J. Martinez, Seema

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice

More information

CD8 CD44 hi but not CD4 CD44 hi memory T cells mediate potent graft antilymphoma activity without GVHD

CD8 CD44 hi but not CD4 CD44 hi memory T cells mediate potent graft antilymphoma activity without GVHD TRANSPLANTATION From www.bloodjournal.org at STANFORD UNIV MED CTR on March 17, 2011. For personal use only. CD8 CD44 hi but not CD4 CD44 hi memory T cells mediate potent graft antilymphoma activity without

More information

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone

More information

Supporting Online Material for

Supporting Online Material for www.sciencemag.org/cgi/content/full/1175194/dc1 Supporting Online Material for A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection John S. Yi, Ming Du, Allan J. Zajac* *To whom

More information

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction

More information

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?

More information

Supplementary Figure 1. Characterization of basophils after reconstitution of SCID mice

Supplementary Figure 1. Characterization of basophils after reconstitution of SCID mice Supplementary figure legends Supplementary Figure 1. Characterization of after reconstitution of SCID mice with CD4 + CD62L + T cells. (A-C) SCID mice (n = 6 / group) were reconstituted with 2 x 1 6 CD4

More information

NK cell flow cytometric assay In vivo DC viability and migration assay

NK cell flow cytometric assay In vivo DC viability and migration assay NK cell flow cytometric assay 6 NK cells were purified, by negative selection with the NK Cell Isolation Kit (Miltenyi iotec), from spleen and lymph nodes of 6 RAG1KO mice, injected the day before with

More information

SUPPLEMENTARY FIGURE 1

SUPPLEMENTARY FIGURE 1 SUPPLEMENTARY FIGURE 1 A LN Cell count (1 ) 1 3 1 CD+ 1 1 CDL lo CD hi 1 CD+FoxP3+ 1 1 1 7 3 3 3 % of cells 9 7 7 % of cells CD+ 3 1 % of cells CDL lo CD hi 1 1 % of CD+ cells CD+FoxP3+ 3 1 % of CD+ T

More information

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/23854 holds various files of this Leiden University dissertation. Author: Marel, Sander van der Title: Gene and cell therapy based treatment strategies

More information

Manipulation of T Cells in the Thnsplant Inoculum

Manipulation of T Cells in the Thnsplant Inoculum International Journal of Cell Cloning 4: 122-126 Suppl 1 (1986) Manipulation of T Cells in the Thnsplant Inoculum J. Kersey Bone Marrow Transplantation Program, University of Minnesota, Minneapolis, MN,

More information

Adaptive immune responses: T cell-mediated immunity

Adaptive immune responses: T cell-mediated immunity MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,

More information

Interferon γ regulates idiopathic pneumonia syndrome, a. Th17 + CD4 + T-cell-mediated GvH disease

Interferon γ regulates idiopathic pneumonia syndrome, a. Th17 + CD4 + T-cell-mediated GvH disease Interferon γ regulates idiopathic pneumonia syndrome, a Th17 + CD4 + T-cell-mediated GvH disease Nora Mauermann, Julia Burian, Christophe von Garnier, Stefan Dirnhofer, Davide Germano, Christine Schuett,

More information

Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine

Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine Biology of Blood and Marrow Transplantation 13:277-292 (2007) 2007 American Society for Blood and Marrow Transplantation 1083-8791/07/1303-0001$32.00/0 doi:10.1016/j.bbmt.2006.11.018 Induction of Immunity

More information

NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies

NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,

More information

Transplantation. Immunology Unit College of Medicine King Saud University

Transplantation. Immunology Unit College of Medicine King Saud University Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the

More information

Memory CD4 + T cells do not induce graft-versus-host disease

Memory CD4 + T cells do not induce graft-versus-host disease Memory CD4 + T cells do not induce graft-versus-host disease See the related Commentary beginning on page 25. Britt E. Anderson, 1 Jennifer McNiff, 2 Jun Yan, 3 Hester Doyle, 3 Mark Mamula, 3 Mark J. Shlomchik,

More information

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation

More information

Umbilical Cord Blood-Derived T Regulatory Cells

Umbilical Cord Blood-Derived T Regulatory Cells Umbilical Cord Blood-Derived T Regulatory Cells David H. McKenna, M.D. PACT Workshop - University of Pittsburgh May 5, 2008 Slide 1 Outline Overview of T regulatory (T R ) cells Potential for clinical

More information

Detailed step-by-step operating procedures for NK cell and CTL degranulation assays

Detailed step-by-step operating procedures for NK cell and CTL degranulation assays Supplemental methods Detailed step-by-step operating procedures for NK cell and CTL degranulation assays Materials PBMC isolated from patients, relatives and healthy donors as control K562 cells (ATCC,

More information

Natural Killer Cells: Development, Diversity, and Applications to Human Disease Dr. Michael A. Caligiuri

Natural Killer Cells: Development, Diversity, and Applications to Human Disease Dr. Michael A. Caligiuri Natural Killer Cells: Development, Diversity, November 26, 2008 The Ohio State University Comprehensive Cancer Center The James Cancer Hospital and Solove Research Institute Columbus, Ohio, USA 1 Human

More information

activation with anti-cd3/cd28 beads and 3d following transduction. Supplemental Figure 2 shows

activation with anti-cd3/cd28 beads and 3d following transduction. Supplemental Figure 2 shows Supplemental Data Supplemental Figure 1 compares CXCR4 expression in untreated CD8 + T cells, following activation with anti-cd3/cd28 beads and 3d following transduction. Supplemental Figure 2 shows the

More information

SUPPLEMENT Supplementary Figure 1: (A) (B)

SUPPLEMENT Supplementary Figure 1: (A) (B) SUPPLEMENT Supplementary Figure 1: CD4 + naïve effector T cells (CD4 effector) were labeled with CFSE, stimulated with α-cd2/cd3/cd28 coated beads (at 2 beads/cell) and cultured alone or cocultured with

More information

TITLE: MODULATION OF T CELL TOLERANCE IN A MURINE MODEL FOR IMMUNOTHERAPY OF PROSTATIC ADENOCARCINOMA

TITLE: MODULATION OF T CELL TOLERANCE IN A MURINE MODEL FOR IMMUNOTHERAPY OF PROSTATIC ADENOCARCINOMA AD Award Number: DAMD17-01-1-0085 TITLE: MODULATION OF T CELL TOLERANCE IN A MURINE MODEL FOR IMMUNOTHERAPY OF PROSTATIC ADENOCARCINOMA PRINCIPAL INVESTIGATOR: ARTHUR A HURWITZ, Ph.d. CONTRACTING ORGANIZATION:

More information

T cell manipulation of the graft: Yes

T cell manipulation of the graft: Yes T cell manipulation of the graft: Yes J.H. Frederik Falkenburg Department of Hematology L M U C Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for non-malignant disorders: no need for anti-tumor

More information

NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity

NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging

More information

Citation Annals of transplantation (2014), 1. use them commercially.

Citation Annals of transplantation (2014), 1.   use them commercially. Induction of alloantigen-specific C Title cells by alloantigen immunization a a pilot study in murine transplanta cardiac allografts. Author(s) Hori, Tomohide; Kuribayashi, Kagema Wang, Linan; Torii, Mie;

More information

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve

More information

The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep

The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep invaders out of the body (pp. 772 773; Fig. 21.1; Table

More information

Supporting Information

Supporting Information Supporting Information lpek et al. 1.173/pnas.1121217 SI Materials and Methods Mice. cell knockout, inos / (Taconic arms), Rag1 /, INγR /, and IL-12p4 / mice (The Jackson Laboratory) were maintained and/or

More information

Modulating STAT Signaling to Promote Engraftment of Allogeneic Bone Marrow Transplant

Modulating STAT Signaling to Promote Engraftment of Allogeneic Bone Marrow Transplant Modulating STAT Signaling to Promote Engraftment of Allogeneic Bone Marrow Transplant Jacopo Mariotti, M.D. Center for Cancer Research, NCI, NIH Istituto Nazionale Tumori, Milano Verona; May 22, 2009 Non-myeloablative

More information

T Cell Development. Xuefang Cao, MD, PhD. November 3, 2015

T Cell Development. Xuefang Cao, MD, PhD. November 3, 2015 T Cell Development Xuefang Cao, MD, PhD November 3, 2015 Thymocytes in the cortex of the thymus Early thymocytes development Positive and negative selection Lineage commitment Exit from the thymus and

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi:10.1038/nature10134 Supplementary Figure 1. Anti-inflammatory activity of sfc. a, Autoantibody immune complexes crosslink activating Fc receptors, promoting activation of macrophages, and WWW.NATURE.COM/NATURE

More information

Supplemental Figure 1. Activated splenocytes upregulate Serpina3g and Serpina3f expression.

Supplemental Figure 1. Activated splenocytes upregulate Serpina3g and Serpina3f expression. Relative Serpin expression 25 2 15 1 5 Serpina3f 1 2 3 4 5 6 8 6 4 2 Serpina3g 1 2 3 4 5 6 C57BL/6 DBA/2 Supplemental Figure 1. Activated splenocytes upregulate Serpina3g and Serpina3f expression. Splenocytes

More information

were isolated from the freshly drawn blood of healthy donors and ACS patients using the

were isolated from the freshly drawn blood of healthy donors and ACS patients using the Supplemental Figure 1. Quality control of CD4 + T-cell purification. CD4 + T cells were isolated from the freshly drawn blood of healthy donors and ACS patients using the RosetteSep CD4 + T Cell Enrichment

More information

MECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW

MECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW MECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW YVON LEBRANCHU Service Néphrologie et Immunologie Clinique CHU TOURS ANTIGEN PRESENTING CELL CD4 + T CELL CYTOKINE PRODUCTION CLONAL

More information

PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human

PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation

More information

1. Overview of Adaptive Immunity

1. Overview of Adaptive Immunity Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive

More information

FOR OPTIMAL GUT HEALTH KEMIN.COM/GUTHEALTH

FOR OPTIMAL GUT HEALTH KEMIN.COM/GUTHEALTH FOR OPTIMAL GUT HEALTH KEMIN.COM/GUTHEALTH ALETA A SOURCE OF 1,3-BETA GLUCANS Aleta is highly bioavailable, offering a concentration greater than 5% of 1,3-beta glucans. Aleta provides a consistent response

More information

Supporting Information

Supporting Information Supporting Information Idoyaga et al. 10.1073/pnas.0812247106 SSC a) Single cell suspension 99 Aqua b) Live cells 96 -W c) Singlets 92 -A CD19+ER119 d) CD19 ER119 cells 97 CD3 e) CD3 cells 27 f) DX5 cells

More information

Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease

Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease Koji Tamada, 1 Hideto Tamura, 1 Dallas Flies, 1 Yang-Xin Fu, 2 Esteban Celis, 1 Larry R.

More information

Chapter 22: The Lymphatic System and Immunity

Chapter 22: The Lymphatic System and Immunity Bio40C schedule Lecture Immune system Lab Quiz 2 this week; bring a scantron! Study guide on my website (see lab assignments) Extra credit Critical thinking questions at end of chapters 5 pts/chapter Due

More information

Immunology Lecture 4. Clinical Relevance of the Immune System

Immunology Lecture 4. Clinical Relevance of the Immune System Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor

More information

Comprehensive evaluation of human immune system reconstitution in NSG. and NSG -SGM3 mouse models toward the development of a novel ONCO-HU

Comprehensive evaluation of human immune system reconstitution in NSG. and NSG -SGM3 mouse models toward the development of a novel ONCO-HU Comprehensive evaluation of human immune system reconstitution in NSG and NSG -SGM3 mouse models toward the development of a novel ONCO-HU xenograft model Aaron Middlebrook, 1 Eileen Snowden, 2 Warren

More information

B6/COLODR/SPL/11C/83/LAP/#2.006 B6/COLODR/SPL/11C/86/LAP/#2.016 CD11C B6/COLODR/SPL/11C/80/LAP/#2.011 CD11C

B6/COLODR/SPL/11C/83/LAP/#2.006 B6/COLODR/SPL/11C/86/LAP/#2.016 CD11C B6/COLODR/SPL/11C/80/LAP/#2.011 CD11C CD3-specific antibody-induced immune tolerance and suppression of autoimmune encephalomyelitis involves TGF-β production through phagocytes digesting apoptotic T cells Sylvain Perruche 1,3, Pin Zhang 1,

More information

From Bench to Bedside Regulatory T Cells: Can We Make the Police Work for Us?

From Bench to Bedside Regulatory T Cells: Can We Make the Police Work for Us? From Bench to Bedside Regulatory T Cells: Can We Make the Police Work for Us? Sang Mo Kang, MD Qizhi Tang, PhD UCSF Division of Transplantation UCSF Transplant Conference 2012 The Reality of Immunosuppression

More information

Introduction to Immunology Part 2 September 30, Dan Stetson

Introduction to Immunology Part 2 September 30, Dan Stetson Introduction to Immunology Part 2 September 30, 2016 Dan Stetson stetson@uw.edu 441 Lecture #2 Slide 1 of 26 CLASS ANNOUNCEMENT PLEASE NO TREE NUTS IN CLASS!!! (Peanuts, walnuts, almonds, cashews, etc)

More information

Mucosal Immune System

Mucosal Immune System Exam Format 100 points - 60 pts mandatory; 40 points where 4, 10 point questions will be chosen Some open-ended questions, some short answer. Kuby question Cytokines Terminology How do cytokines achieve

More information

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses

More information

Mon, Wed, Fri 11:00 AM-12:00 PM. Owen, Judy, Jenni Punt, and Sharon Stranford Kuby-Immunology, 7th. Edition. W.H. Freeman and Co., New York.

Mon, Wed, Fri 11:00 AM-12:00 PM. Owen, Judy, Jenni Punt, and Sharon Stranford Kuby-Immunology, 7th. Edition. W.H. Freeman and Co., New York. Course Title: Course Number: Immunology Biol-341/541 Semester: Fall 2013 Location: HS 268 Time: Instructor: 8:00-9:30 AM Tue/Thur Dr. Colleen M. McDermott Office: Nursing Ed 101 (424-1217) E-mail*: mcdermot@uwosh.edu

More information

FIT Board Review Corner March 2016

FIT Board Review Corner March 2016 FIT Board Review Corner March 2016 Welcome to the FIT Board Review Corner, prepared by Sarah Spriet, DO, and Tammy Peng, MD, senior and junior representatives of ACAAI's Fellows-In-Training (FITs) to the

More information

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS 1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family

More information

In vitro human regulatory T cell suppression assay

In vitro human regulatory T cell suppression assay Human CD4 + CD25 + regulatory T cell isolation, in vitro suppression assay and analysis In vitro human regulatory T cell suppression assay Introduction Regulatory T (Treg) cells are a subpopulation of

More information

SEVENTH EDITION CHAPTER

SEVENTH EDITION CHAPTER Judy Owen Jenni Punt Sharon Stranford Kuby Immunology SEVENTH EDITION CHAPTER 16 Tolerance, Autoimmunity, and Transplantation Copyright 2013 by W. H. Freeman and Company Immune tolerance: history * Some

More information

Sipper BK Experimental Animal Co. (Shanghai, China) and bred in a specific. pathogen-free environment. The animal study protocol was approved by the

Sipper BK Experimental Animal Co. (Shanghai, China) and bred in a specific. pathogen-free environment. The animal study protocol was approved by the Supplementary information, Data S1 Materials and Methods Mice, Ad vectors and reagents Female C57BL/6 mice, 8-10 weeks of age, were purchased from Joint Ventures Sipper BK Experimental Animal Co. (Shanghai,

More information

Supplementary Figure S1. Flow cytometric analysis of the expression of Thy1 in NH cells. Flow cytometric analysis of the expression of T1/ST2 and

Supplementary Figure S1. Flow cytometric analysis of the expression of Thy1 in NH cells. Flow cytometric analysis of the expression of T1/ST2 and Supplementary Figure S1. Flow cytometric analysis of the expression of Thy1 in NH cells. Flow cytometric analysis of the expression of T1/ST2 and Thy1 in NH cells derived from the lungs of naïve mice.

More information

LESSON 2: THE ADAPTIVE IMMUNITY

LESSON 2: THE ADAPTIVE IMMUNITY Introduction to immunology. LESSON 2: THE ADAPTIVE IMMUNITY Today we will get to know: The adaptive immunity T- and B-cells Antigens and their recognition How T-cells work 1 The adaptive immunity Unlike

More information

B220 CD4 CD8. Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN

B220 CD4 CD8. Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN B220 CD4 CD8 Natarajan et al., unpublished data Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN showing B cell follicles and T cell areas. 20 µm thick. Image of magnification

More information

Immune Regulation and Tolerance

Immune Regulation and Tolerance Immune Regulation and Tolerance Immunoregulation: A balance between activation and suppression of effector cells to achieve an efficient immune response without damaging the host. Activation (immunity)

More information

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features Loretta Gammaitoni, Lidia Giraudo, Valeria Leuci, et al. Clin Cancer Res

More information

Nature Immunology: doi: /ni Supplementary Figure 1. Examples of staining for each antibody used for the mass cytometry analysis.

Nature Immunology: doi: /ni Supplementary Figure 1. Examples of staining for each antibody used for the mass cytometry analysis. Supplementary Figure 1 Examples of staining for each antibody used for the mass cytometry analysis. To illustrate the functionality of each antibody probe, representative plots illustrating the expected

More information

Advances in Cancer Immunotherapy

Advances in Cancer Immunotherapy Advances in Cancer Immunotherapy Immunology 101 for the Non-Immunologist Arnold H. Zea, PhD azea@lsuhsc.edu Disclosures No relevant financial relationships to disclose This presentation does not contain

More information

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes

More information

RAISON D ETRE OF THE IMMUNE SYSTEM:

RAISON D ETRE OF THE IMMUNE SYSTEM: RAISON D ETRE OF THE IMMUNE SYSTEM: To Distinguish Self from Non-Self Thereby Protecting Us From Our Hostile Environment. Innate Immunity Acquired Immunity Innate immunity: (Antigen nonspecific) defense

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Supplemental Figure 1. Furin is efficiently deleted in CD4 + and CD8 + T cells. a, Western blot for furin and actin proteins in CD4cre-fur f/f and fur f/f Th1 cells. Wild-type and furin-deficient CD4 +

More information

Nature Immunology: doi: /ni Supplementary Figure 1. Huwe1 has high expression in HSCs and is necessary for quiescence.

Nature Immunology: doi: /ni Supplementary Figure 1. Huwe1 has high expression in HSCs and is necessary for quiescence. Supplementary Figure 1 Huwe1 has high expression in HSCs and is necessary for quiescence. (a) Heat map visualizing expression of genes with a known function in ubiquitin-mediated proteolysis (KEGG: Ubiquitin

More information

Supplementary Figures

Supplementary Figures Supplementary Figures Supplementary Fig. 1. Surface thiol groups and reduction of activated T cells. (a) Activated CD8 + T-cells have high expression levels of free thiol groups on cell surface proteins.

More information

Chapter 13 Lymphatic and Immune Systems

Chapter 13 Lymphatic and Immune Systems The Chapter 13 Lymphatic and Immune Systems 1 The Lymphatic Vessels Lymphoid Organs Three functions contribute to homeostasis 1. Return excess tissue fluid to the bloodstream 2. Help defend the body against

More information

pplementary Figur Supplementary Figure 1. a.

pplementary Figur Supplementary Figure 1. a. pplementary Figur Supplementary Figure 1. a. Quantification by RT-qPCR of YFV-17D and YFV-17D pol- (+) RNA in the supernatant of cultured Huh7.5 cells following viral RNA electroporation of respective

More information

Supporting Information

Supporting Information Supporting Information Pang et al. 10.1073/pnas.1322009111 SI Materials and Methods ELISAs. These assays were performed as previously described (1). ELISA plates (MaxiSorp Nunc; Thermo Fisher Scientific)

More information

VMC-221: Veterinary Immunology and Serology (1+1) Question Bank

VMC-221: Veterinary Immunology and Serology (1+1) Question Bank VMC-221: Veterinary Immunology and Serology (1+1) Objective type Questions Question Bank Q. No. 1 - Fill up the blanks with correct words 1. The British physician, who developed the first vaccine against

More information

The Contribution of Homeostatically Expanded Donor CD8 T Cells to Host Reconstitution Following Syngeneic Hematopoietic Cell Transplantation

The Contribution of Homeostatically Expanded Donor CD8 T Cells to Host Reconstitution Following Syngeneic Hematopoietic Cell Transplantation University of Miami Scholarly Repository Open Access Dissertations Electronic Theses and Dissertations 2008-07-24 The Contribution of Homeostatically Expanded Donor CD8 T Cells to Host Reconstitution Following

More information

A crucial role for HVEM and BTLA in preventing intestinal inflammation

A crucial role for HVEM and BTLA in preventing intestinal inflammation Washington University School of Medicine Digital Commons@Becker Open Access Publications 2008 A crucial role for HVEM and BTLA in preventing intestinal inflammation Marcos W. Steinberg La Jolla Institute

More information

Question 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell?

Question 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell? Abbas Chapter 2: Sarah Spriet February 8, 2015 Question 1. Kupffer cells, microglial cells and osteoclasts are all examples of what type of immune system cell? a. Dendritic cells b. Macrophages c. Monocytes

More information

Adaptive (acquired) immunity. Professor Peter Delves University College London

Adaptive (acquired) immunity. Professor Peter Delves University College London Adaptive (acquired) immunity Professor Peter Delves University College London p.delves@ucl.ac.uk Haematopoiesis Haematopoiesis Lymphocytes = adaptive response Recognition of pathogens by adaptive cells,

More information

CD34+ Cells: A Comparison of Stem and Progenitor Cells in Cord Blood, Peripheral Blood, and the Bone Marrow

CD34+ Cells: A Comparison of Stem and Progenitor Cells in Cord Blood, Peripheral Blood, and the Bone Marrow White Paper September 2016 CD34+ Cells: A Comparison of Stem and Progenitor Cells in Cord Blood, Peripheral Blood, and the Bone Marrow Lily C. Trajman, PhD Introduction: Hematopoietic Stem Cells (HSCs)

More information

Cell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice

Cell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice Supplementary Methods: Cell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice and gently meshed in DMEM containing 10% FBS to prepare for single cell suspensions. CD4 + CD25

More information

Eosinophils are required. for the maintenance of plasma cells in the bone marrow

Eosinophils are required. for the maintenance of plasma cells in the bone marrow Eosinophils are required for the maintenance of plasma cells in the bone marrow Van Trung Chu, Anja Fröhlich, Gudrun Steinhauser, Tobias Scheel, Toralf Roch, Simon Fillatreau, James J. Lee, Max Löhning

More information

The Lymphatic System and Body Defenses

The Lymphatic System and Body Defenses PowerPoint Lecture Slide Presentation by Patty Bostwick-Taylor, Florence-Darlington Technical College The Lymphatic System and Body Defenses 12PART B Adaptive Defense System: Third Line of Defense Immune

More information

Pearson r = P (one-tailed) = n = 9

Pearson r = P (one-tailed) = n = 9 8F4-Specific Lysis, % 1 UPN1 UPN3 8 UPN7 6 Pearson r =.69 UPN2 UPN5 P (one-tailed) =.192 4 UPN8 n = 9 2 UPN9 UPN4 UPN6 5 1 15 2 25 8 8F4, % Max MFI Supplementary Figure S1. AML samples UPN1-UPN9 show variable

More information

Supplementary Materials for

Supplementary Materials for www.sciencemag.org/content/348/6241/aaa825/suppl/dc1 Supplementary Materials for A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells Georg Stary,* Andrew Olive,

More information

McAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells

McAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells Effects of McAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells X.C. Wei, D.D. Yang, X.R. Han, Y.A. Zhao, Y.C. Li, L.J. Zhang and J.J. Wang Institute of hematological research,

More information

CD4 + CD25 + Reactions

CD4 + CD25 + Reactions Send Orders for Reprints to reprints@benthamscience.net CD4 + CD25 + Reactions The Open Autoimmunity Journal, 2013, 5, 1-5 1 Open Access Regulatory T Cells Preventing Detrimental Autoimmune Muhaimin Rifa

More information

CHAPTER 3 LABORATORY PROCEDURES

CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified

More information

Supplementary Figure 1. Example of gating strategy

Supplementary Figure 1. Example of gating strategy Supplementary Figure 1. Example of gating strategy Legend Supplementary Figure 1: First, gating is performed to include only single cells (singlets) (A) and CD3+ cells (B). After gating on the lymphocyte

More information

Qualitative Changes Accompany Memory T Cell Generation: Faster, More Effective Responses at Lower Doses of Antigen

Qualitative Changes Accompany Memory T Cell Generation: Faster, More Effective Responses at Lower Doses of Antigen This information is current as of July 5, 2018. Qualitative Changes Accompany Memory T Cell Generation: Faster, More Effective Responses at Lower Doses of Antigen Paul R. Rogers, Caroline Dubey and Susan

More information

Allogeneic bone marrow transplantation (BMT)

Allogeneic bone marrow transplantation (BMT) Photochemical Treatment with S-59 Psoralen and Ultraviolet A Light to Control the Fate of Naive or Primed T Lymphocytes In Vivo After Allogeneic Bone Marrow Transplantation 1 Robert L. Truitt, 2 * Bryon

More information

Children's Hospital of Pittsburgh Annual Progress Report: 2011 Formula Grant

Children's Hospital of Pittsburgh Annual Progress Report: 2011 Formula Grant Children's Hospital of Pittsburgh Annual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The Children's Hospital of Pittsburgh received $228,401 in

More information

- Transplantation: removing an organ from donor and gives it to a recipient. - Graft: transplanted organ.

- Transplantation: removing an organ from donor and gives it to a recipient. - Graft: transplanted organ. Immunology Lecture num. (21) Transplantation - Transplantation: removing an organ from donor and gives it to a recipient. - Graft: transplanted organ. Types of Graft (4 types): Auto Graft - From a person

More information

Islet viability assay and Glucose Stimulated Insulin Secretion assay RT-PCR and Western Blot

Islet viability assay and Glucose Stimulated Insulin Secretion assay RT-PCR and Western Blot Islet viability assay and Glucose Stimulated Insulin Secretion assay Islet cell viability was determined by colorimetric (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide assay using CellTiter

More information

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand

More information